Dyax Corp. to Participate in the 14th Annual Needham Healthcare Conference
April 09 2015 - 8:00AM
Business Wire
Dyax Corp. (NASDAQ:DYAX) announced today that executive
management will participate in the 14th Annual Needham Healthcare
Conference being held April 14-15, 2015 at the Westin Grand Central
Hotel in New York City. The Company is scheduled to present on
Tuesday, April 14 at 11:20am (ET) and will provide a corporate
update on DX-2930, the KALBITOR® (ecallantide) business and the
Licensing and Funded Research Portfolio (LFRP).
The presentation will be webcast live and may be accessed by
visiting the Investor Relations section of the company’s website at
http://investor.dyax.com/events.cfm. The webcast will also be
available on the Dyax website for a limited period of time
following the conference.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on
the development and commercialization of novel biotherapeutics for
unmet medical needs. The Company currently markets KALBITOR®
(ecallantide) for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 12 years of age and older. Dyax is
also developing DX-2930, a fully human monoclonal antibody, for the
potential prophylactic treatment of HAE.
Both KALBITOR and DX-2930 were identified using Dyax's
proprietary phage display technology. Dyax has broadly licensed
this technology under its Licensing and Funded Research Portfolio
(LFRP). The current portfolio includes one FDA approved product,
Eli Lilly and Company’s CYRAMZA® (ramucirumab), for which Dyax
receives royalties, and multiple product candidates in various
stages of clinical development for which the Company is eligible to
receive future milestones and/or royalties.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking statements.
Statements that are not historical facts are based on Dyax's
current expectations, beliefs, assumptions, estimates, forecasts
and projections about the industry and markets in which Dyax
operates. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements because of
risks, uncertainties and assumptions involved in any future
projections. There are many factors that could cause actual results
to differ from these forward-looking statements, including: risks
and uncertainties relating to the clinical development and
regulatory approval of DX-2930; Dyax's dependence on the expertise,
effort, priorities and contractual obligations of third parties in
the development of DX-2930 and in the marketing, sales and
distribution of KALBITOR; competition from new and existing
treatments for HAE; the uncertainty of patent and intellectual
property protection relating to DX-2930, KALBITOR and the LFRP;
Dyax's dependence on licensees and collaborators for development,
clinical trials, manufacturing, sales and distribution of product
candidates in the LFRP; uncertainties as to whether one or more
product candidates in the LFRP will achieve development and
regulatory milestones and be commercialized and generate royalties;
uncertainties regarding Lilly's ability to successfully market
CYRAMZA for the treatment of advanced gastric cancer; and other
risk factors described or referred to in Item 1A, "Risk Factors" in
Dyax's most recent Annual Report on Form 10-K and other periodic
reports filed with the Securities and Exchange Commission. Dyax
cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this release, and Dyax
undertakes no obligations to update or revise these statements,
except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered marks of Dyax
Corp.CYRAMZA® is a registered trademark of Eli Lilly and
Company.
Dyax Corp.Jennifer Robinson, 617-250-5741Director, Investor
Relations and Corporate Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Apr 2023 to Apr 2024